Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long‐term results
HPB, ISSN: 1365-182X, Vol: 15, Issue: 8, Page: 595-601
2013
- 35Citations
- 34Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations35
- Citation Indexes35
- 35
- CrossRef26
- Captures34
- Readers34
- 34
Article Description
Radiofrequency ablation (RFA) has been used to treat hepatocellular carcinoma (HCC) and liver metastases for more than 10 years with promising early outcomes. Preliminary results comparing percutaneous and surgical approaches have shown no difference in short‐term outcomes. In this study, the longer‐term outcomes were presented. Patients with liver malignancies treated by RFA were prospectively studied from 2003 to 2011. Post‐ablation assessment by computed tomography (CT) scan and serum biochemistry was performed at regular intervals. Recurrence rates and long‐term survival were analysed. A total of 233 patients with liver malignancies (75.5% HCC and 24.5% liver metastases) were analysed. Three RFA approaches were used (percutaneous 58.4%, laparoscopic 9.4% and open 32.2%). The median follow‐up time was 29 months. Complete ablation was achieved in 83.7%, with no difference between the two approaches. More wound and chest complications were observed in the surgical group. Intra‐hepatic recurrences were observed in 69.5%; extra‐hepatic recurrences were detected in 22.3%, with no difference between the two groups. There was no statistical difference between the two approaches in overall 1‐, 3‐ and 5‐year survival. An extended period of follow‐up in patients with liver malignancies showed that RFA is an effective treatment. No difference was demonstrated between the percutaneous and surgical approach, in terms of recurrence and survival.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1365182X15314441; http://dx.doi.org/10.1111/hpb.12014; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84880146574&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23458320; https://linkinghub.elsevier.com/retrieve/pii/S1365182X15314441; http://www.hpbonline.org/article/S1365-182X(15)31444-1/abstract
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know